CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.
The findings of the randomized phase 3 noninferiority trial, presented at ASCO Annual Meeting, suggested concurrent chemotherapy (CCRT) could be safely omitted for patients who receive intensity-modulated radiotherapy (IMRT).
“As we know, concurrent chemoradiotherapy with or without induction or adjuvant chemotherapy has been the standard modality